SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets USFDA’s approval for Azacitidine for Injection, 100 mg Single-Dose Vial

28 Feb 2019 Evaluate

Lupin has received approval for its Azacitidine for Injection, 100 mg Single-Dose Vial from the United States Food and Drug Administration (USFDA) to market a generic version of Celgene Corporation’s Vidaza. With this approval, Lupin strengthens its complex generics portfolio in Injectables.

Lupin’s Azacitidine for Injection, 100 mg Single-Dose Vial is a generic version of Celgene Corporation’s Vidaza. It is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

Azacitidine for Injection, 100 mg Single-Dose Vial had annual sales of approximately $112 million in the US (IQVIA MAT December 2018).

Lupin’s state-of-the-art Mihan facility at Nagpur commissioned recently has the production capabilities for injectables with vials, Iyophilised vials and Pre-filled Syringes (PFS). It received an EIR from USFDA in December 2018.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×